Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « ISSN » - entrée « 1468-2060 »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
1468-201X < 1468-2060 < 1468-2079  Facettes :

List of bibliographic references indexed by 1468-2060

Number of relevant bibliographic references: 78.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000034 (2021) Ennio Giulio Favalli [Oman] ; Francesca Ingegnoli [Italie] ; Rolando Cimaz [Italie] ; Roberto Caporali [Italie]What is the true incidence of COVID-19 in patients with rheumatic diseases?
000066 (2021) Kim Lauper [Suisse, Royaume-Uni] ; Johannes W J. Bijlsma [Pays-Bas] ; Gerd R. Burmester [Allemagne]Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic.
000072 (2021) Konstantinos Parperis [Chypre (pays), États-Unis]To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
000131 (2021) Carmen Magdalena Gamboa-Alonso [Mexique] ; Gabriel Figueroa-Parra [Mexique] ; Dionicio Angel Galarza-Delgado [Mexique]Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie et al.
000164 (2021) Mohit Goyal [Oman]SLE patients are not immune to covid-19: importance of sending the right message across.
000177 (2021) Kevin L. Winthrop [États-Unis] ; Amanda E. Brunton [États-Unis] ; Susan Beekmann [États-Unis] ; Philip Polgreen [États-Unis] ; John Baddley [États-Unis] ; Kenneth G. Saag [États-Unis] ; Cassandra Calabrese [États-Unis] ; Leonard Calabrese [États-Unis] ; Philip C. Robinson [Australie] ; Zachary S. Wallace [États-Unis] ; Jeffrey R. Curtis [États-Unis]SARS CoV-2 infection among patients using immunomodulatory therapies.
000182 (2021) Philippe Guilpain [France] ; Clément Le Bihan [France] ; Vincent Foulongne [France] ; Patrice Taourel [France] ; Nathalie Pansu [France] ; Alexandre Thibault Jacques Maria [France] ; Boris Jung [France] ; Romaric Larcher [France] ; Kada Klouche [France] ; Vincent Le Moing [France]Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.
000192 (2021) Alexis Mathian [France] ; Zahir Amoura [France]Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al.
000198 (2021) Francesca Romana Spinelli [Italie] ; Fulvia Ceccarelli [Italie] ; Manuela Di Franco [Italie] ; Fabrizio Conti [Italie]Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.
000199 (2021) Francesca Romana Spinelli [Italie] ; Fulvia Ceccarelli [Italie] ; Manuela Di Franco [Italie] ; Fabrizio Conti [Italie]Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.
000286 (2021) Amr H. Sawalha [États-Unis]Patients with lupus are not protected from COVID-19.
000300 (2021) Vasco C. Romão [Portugal] ; Ana Rita Cruz-Machado [Portugal] ; João Eurico Fonseca [Oman, Portugal]No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit.
000360 (2021) Sergey Moiseev [Oman] ; Sergey Avdeev [Russie] ; Michail Brovko [Russie] ; Pavel Novikov [Russie] ; Victor Fomin [Russie]Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
000393 (2021) Alessia Alunno [Oman] ; Aurélie Najm [Royaume-Uni] ; Xavier Mariette [France] ; Gabriele De Marco [Royaume-Uni] ; Jenny Emmel [Royaume-Uni] ; Laura Mason [Royaume-Uni] ; Dennis G. Mcgonagle [Royaume-Uni] ; Pedro M. Machado [Royaume-Uni]Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
000416 (2021) Arielle Mendel [Canada] ; Sasha Bernatsky [Canada] ; Anca Askanase [États-Unis] ; Sang-Cheol Bae [Corée du Sud] ; Ann Elaine Clarke [Canada] ; Nathalie Costedoat-Chalumeau [France] ; Dafna D. Gladman [Canada] ; Caroline Gordon [Royaume-Uni] ; John Hanly [Canada] ; S Ren Jacobsen [Danemark] ; Ken Kalunian [États-Unis] ; Anselm Mak [Singapour] ; Marta Mosca [Italie] ; Bernardo A. Pons-Estel [Argentine] ; Guillermo Ruiz-Irastorza [Espagne] ; Murray Urowitz [Canada] ; Évelyne Vinet [Canada]Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
000418 (2021) Wenhui Xie [République populaire de Chine] ; Yu Wang [République populaire de Chine] ; Zhuoli Zhang [Oman]Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
000580 (2021) Hercílio Martelli Júnior [Brésil] ; Nelson Pereira Marques [Oman] ; Nádia Carolina Teixeira Marques [Brésil] ; Edson Gomes De Lucena [Brésil] ; Daniella Reis B. Martelli [Brésil] ; Eduardo A. Oliveira [Brésil]Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
000581 (2021) Sarthak Gupta ; Shuichiro Nakabo [États-Unis] ; Jun Chu [États-Unis] ; Sarfaraz Hasni [États-Unis] ; Mariana J. Kaplan [États-Unis]Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
000599 (2021) Sara Monti [Oman] ; Carlomaurizio Montecucco [Italie]Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al.
000724 (2021) Ennio Giulio Favalli [Oman] ; Maria Gerosa [Italie] ; Antonella Murgo [Italie] ; Roberto Caporali [Italie]Are patients with systemic lupus erythematosus at increased risk for COVID-19?
000A51 (2020) Rita Angélica Pineda-Sic [Mexique] ; Dionicio Angel Galarza-Delgado [Mexique] ; Griselda Serna-Pe A [Mexique] ; Sergio A. Castillo-Torres [Mexique] ; Diana Elsa Flores-Alvarado [Mexique] ; Jorge A. Esquivel-Valerio [Mexique] ; Iván De Jesús Hernández-Galarza [Mexique]Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1468-2060" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1468-2060" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1468-2060
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021